Outpost Bio is decoding the hidden interactions that drive human biology. The company combines high-throughput assays of human-derived microbial communities with machine learning to build frontier models that reveal causal pathways - not just correlations. Headquartered in Boston and London, the company enables any partner developing molecules that go into or onto humans to predict microbe-mediated metabolism, toxicity, and response - making human microbiology computable for the first time.
- Life Sciences
- London, United Kingdom
- £2.6m
- outpost.bio
- Update Information
More venture news
- 2 Mar 2026


Outpost Bio secures a £2.6m pre-seed round led by Merantix Capital and Seedcamp to make human microbiology computable
Pre-seedLife Sciences - 25 Feb 2026


Sonas Pharma secures pre-seed funding led by SFC Capital to develop therapeutics for obesity and epilepsy
Pre-seedLife Sciences - 13 Jan 2026


Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs
SeedLife Sciences
